Fusion Antibodies PLC
LSE:FAB
P/S
Price to Sales
Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.
Market Cap | P/S | ||||
---|---|---|---|---|---|
UK |
Fusion Antibodies PLC
LSE:FAB
|
3.2m GBP | 2.1 | ||
US |
Thermo Fisher Scientific Inc
NYSE:TMO
|
220.9B USD | 5.2 | ||
US |
Danaher Corp
NYSE:DHR
|
182.8B USD | 4.2 | ||
CH |
Lonza Group AG
SIX:LONN
|
37.5B CHF | 5.6 | ||
KR |
Samsung Biologics Co Ltd
KRX:207940
|
55.2T KRW | 14.9 | ||
US |
IQVIA Holdings Inc
NYSE:IQV
|
40.3B USD | 2.7 | ||
US |
Agilent Technologies Inc
NYSE:A
|
40.3B USD | 6 | ||
US |
Mettler-Toledo International Inc
NYSE:MTD
|
26.9B USD | 7.1 | ||
US |
West Pharmaceutical Services Inc
NYSE:WST
|
26.9B USD | 9.2 | ||
IE |
ICON PLC
NASDAQ:ICLR
|
24.9B USD | 3 | ||
FR |
Sartorius Stedim Biotech SA
PAR:DIM
|
19.2B EUR | 7.1 |
P/S Forward Multiples
Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.